UK-based pharmaceutical company AstraZeneca has announced that its Tagrisso (osimertinib) has been approved by the Japanese Ministry of Health, Labour...
Read More...
The post AstraZeneca’s Tagrisso approved in Japan for EGFR-mutated NSCLC appeared first on Pharmaceutical Technology.
Original Article: AstraZeneca’s Tagrisso approved in Japan for EGFR-mutated NSCLC